Interpretation on the <i>Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association</i>(<i>2022</i>)

LIANG Yun; WU Wenming; NIE Yongzhan; CHEN Jie

doi:10.12290/xhyxzz.2022-0607

Volume 14 Issue 1

Jan. 2023

Turn off MathJax

Article Contents

Abstract

References

Medical Journal of Peking Union Medical College Hospital > 2023 > 14(1): 94-100. > DOI: 10.12290/xhyxzz.2022-0607

LIANG Yun, WU Wenming, NIE Yongzhan, CHEN Jie. Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 94-100. DOI: 10.12290/xhyxzz.2022-0607

Citation:

PDF (468 KB)

Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)

LIANG Yun^{1, 2},
WU Wenming^3, ,,
NIE Yongzhan^4, ,,
CHEN Jie^{1, 2, ,}

1.
Center for Neuroendocrine Tumors, Department of Head & Neck Tumors and Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai 200032, China
2.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3.
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
4.
Department of Gastroenterology, Xijing Hospital, Air Force Medical University, Xi'an 710032, China

Funds:

National Natural Science Foundation of China 82141104

More Information

Corresponding author:
WU Wenming, E-mail: wuwm@pumch.cn

NIE Yongzhan, E-mail: yongznie@fmmu.edu.cn

CHEN Jie, E-mail: chen0jie@hotmail.com
Received Date: October 17, 2022
Accepted Date: December 04, 2022
Available Online: January 15, 2023
Issue Publish Date: January 29, 2023

Graphical Abstract

Abstract

Abstract

Neuroendocrine neoplasms (NENs) are a group of malignancies arising from neuroendocrine cells and peptidergic neurons. The high heterogeneity of NENs leads to challenges and complexities in its diagnosis and treatment. Experts from relevant disciplines were convened by the Society of Neuroendocrine neoplasm of China Anti-Cancer Association to develop this first edition of the Chinese Guideline for diagnosis and treatment of NENs (2022) based on existing evidence combined with domestic and international guidelines and consensus. In this article, we summarize the important contents of this guideline and make further discussion on some controversial issues, with the aim to provide treatment reference in clinical practice.
- neuroendocrine neoplasms,
- diagnosis,
- treatment,
- guideline,
- interpretation

FullText(HTML)

References (38)

References

[1]	Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States[J]. JAMA Oncol, 2017, 3: 1335-1342. DOI: 10.1001/jamaoncol.2017.0589
[2]	Fang C, Wang W, Zhang Y, et al. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China[J]. Chin J Cancer, 2017, 36: 51. DOI: 10.1186/s40880-017-0218-3
[3]	Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Func-tional Pancreatic Neuroendocrine Tumors[J]. Neuroendocrinology, 2016, 103: 153-171. DOI: 10.1159/000443171
[4]	Kamilaris CDC, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis[J]. Front Endocrinol (Lausanne), 2019;10: 339. DOI: 10.3389/fendo.2019.00339
[5]	Puliani G, Di Vito V, Feola T, et al. NETest: A Systematic Review Focusing on the Prognostic and Predictive Role[J]. Neuroendocrinology, 2022, 112: 523-536. DOI: 10.1159/000518873
[6]	Malczewska A, Kos-Kudła B, Kidd M, et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors[J]. Adv Med Sci, 2020, 65: 18-29. DOI: 10.1016/j.advms.2019.10.002
[7]	Chen L, Guo Y, Zhang Y, et al. Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors[J]. Endoscopy, 2021, 53: 702-709. DOI: 10.1055/a-1274-0161
[8]	Luo Y, Chen J, Huang K, et al. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?[J]. BMC Cancer, 2017, 17: 154. DOI: 10.1186/s12885-017-3150-7
[9]	Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_GETNE1504 study)[J]. Br J Cancer, 2019, 121: 537-544. DOI: 10.1038/s41416-019-0558-7
[10]	Chen L, Wang W, Jin K, et al. Special issue "the advane of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors[J]. Int J Cancer, 2023, 152: 90-99. DOI: 10.1002/ijc.34294
[11]	Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and ¹⁸F-FDG[J]. Cancer, 2008, 112: 2447-2455. DOI: 10.1002/cncr.23469
[12]	Panagiotidis E, Alshammari A, Michopoulou S, et al. Comparison of the Impact of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors[J]. J Nucl Med, 2016, 58: 91-96.
[13]	Rinzivillo M, Partelli S, Prosperi D, et al. Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms[J]. Oncologist, 2018, 23: 186-192. DOI: 10.1634/theoncologist.2017-0278
[14]	Kim YI, Yoo C, Oh SJ, et al. Tumour-to-liver ratio determined by[(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours[J]. EJNMMI Res, 2020, 10: 63. DOI: 10.1186/s13550-020-00651-z
[15]	Kuik WJ, Kema IP, Brouwers AH, et al. In vivo biodistribution of no-carrier-added 6-¹⁸F-fluoro-3, 4-dihydroxy-L-phenylalanine (¹⁸F-DOPA), produced by a new nucleo-philic substitution approach, compared with carrier-added (¹⁸F-DOPA), prepared by conventional electrophilic substitution[J]. J Nucl Med, 2015, 56: 106-112. DOI: 10.2967/jnumed.114.145730
[16]	Piccardo A, Lopci E, Conte M, et al. Comparison of ¹⁸F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study[J]. Eur J Nucl Med Mol Imaging, 2012, 39: 57-71. DOI: 10.1007/s00259-011-1938-2
[17]	Luo Y, Pan Q, Yao S, et al. Glucagon-like Peptide-1 Receptor PET/CT with ⁶⁸Ga-NOTA-exendin-4 for Detecting Localized Insulinoma: a Prospective Cohort Study[J]. J Nucl Med, 2016, 57: 715-720. DOI: 10.2967/jnumed.115.167445
[18]	WHO Classification of Tumours Editorial Board. WHO classification of tumours, 5th Edition, Volume 1: Digestive System Tumours[M]. Lyon: IARC Press, 2019.
[19]	WHO Classification of Tumours Editorial Board. WHO Classification of Tumours, 5th Edition, Volume 5: Thoracic Tumours[M]. Lyon: IARC Press, 2021.
[20]	Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart[J]. J Thorac Oncol, 2015, 10: 1240-1242. DOI: 10.1097/JTO.0000000000000663
[21]	Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal[J]. Mod Pathol, 2018, 31: 1770-1786. DOI: 10.1038/s41379-018-0110-y
[22]	Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms[J]. Endocr Pathol, 2022, 33: 115-154. DOI: 10.1007/s12022-022-09708-2
[23]	Chivukula SV, Tierney JF, Hertl M, et al. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over-or undertreating patients?[J]. Surgery, 2020, 167: 180-186. DOI: 10.1016/j.surg.2019.04.061
[24]	Dong DH, Zhang XF, Poultsides G, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm after curative resection: A multi-institutional study of 392 cases[J]. J Surg Oncol, 2019, 120: 1071-1079. DOI: 10.1002/jso.25716
[25]	Lopez-Aguiar AG, Zaidi MY, Beal EW, et al. Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: An eight-institution study of 695 patients from the US neuroendocrine tumor study group[J]. Ann Surg Oncol, 2019, 26: 2517-2524. DOI: 10.1245/s10434-019-07367-y
[26]	Guarneri G, de Mestier L, Landoni L, et al. Prognostic role of examined and positive lymph nodes after distal pancreatectomy for non-functioning neuroendocrine neoplasms[J]. Neuroendocrinology, 2021, 111: 728-738. DOI: 10.1159/000509709
[27]	Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371: 224-233. DOI: 10.1056/NEJMoa1316158
[28]	Rinke A, Müller HH, Schade-Brittinger C, et al. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroen-docrine midgut tumors: a report from the PROMID Study Group[J]. J Clin Oncol, 2009, 27: 4656-4663. DOI: 10.1200/JCO.2009.22.8510
[29]	Liu Y, Liu H, Chen W, et al. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden[J]. Cancer Med, 2022, 11: 2588-2600. DOI: 10.1002/cam4.4628
[30]	Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?[J]. J Hepatol, 2007, 47: 460-466. DOI: 10.1016/j.jhep.2007.07.004
[31]	中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J]. 中国癌症杂志, 2022, 32: 545-580. Society of Neuroendocrine Neoplasm of China Anti-Cancer Association. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)[J]. Zhongguo Aizheng Zazhi, 2022, 32: 545-580.
[32]	Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas[J]. Neuroendocrinology, 2016, 103: 186-194. DOI: 10.1159/000443172
[33]	National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors (Version 2021)[EB/OL]. [2021-06-18]. https://www.nccn.org/guidelines/guidelines-detail?cate-gory=1&id=1448.
[34]	Bongiovanni A, Liverani C, Foca F, et al. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis[J]. Neuroendocrinology, 2021, 111: 895-906. DOI: 10.1159/000513218
[35]	Wang W, Zhang Y, Peng Y, et al. A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolo-mide Regimen in Neuroendocrine Neoplasms: A Retrospec-tive Multicenter Study[J]. Neuroendocrinology, 2021, 111: 752-763. DOI: 10.1159/000510159
[36]	Apostolidis L, Dal Buono A, Merola E, et al. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)[J]. Cancers, 2021, 13: 1936. DOI: 10.3390/cancers13081936
[37]	Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 379: 2220-2229. DOI: 10.1056/NEJMoa1809064
[38]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394: 1929-1939. DOI: 10.1016/S0140-6736(19)32222-6

[1]	TIAN Zhuang, ZHANG Shuyang. Interpretation on Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 801-806. DOI: 10.12290/xhyxzz.2024-0292
[2]	LIANG Yan. Interpretation on the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines for the Management of Patients with Chronic Coronary Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 312-319. DOI: 10.12290/xhyxzz.2024-0043
[3]	WANG Yongxuan, LI Mei, ZHANG Zhenlin, XIA Weibo. Interpretation on the Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1203-1207. DOI: 10.12290/xhyxzz.2023-0364
[4]	CHEN Rong. Interpretation on the 2023 Chinese Menopause Symptom Management and Menopausal Hormone Therapy Guidelines[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 514-519. DOI: 10.12290/xhyxzz.2023-0190
[5]	WU Juelun, SHEN Le. Evaluation, Preparation, Decision, and Oxygenation: Interpretation on 2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 421-426. DOI: 10.12290/xhyxzz.2022-0075
[6]	WANG Lin, SONG Hongmei. Interpretation on Chinese Guidelines for the Diagnosis and Treatment of Childhood-onset Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 412-420. DOI: 10.12290/xhyxzz.2022-0018
[7]	Yun WANG, Ze-hao WU, Yu-guang HUANG. Standardization and Normalization: Interpretation on Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery after Surgery Society Recommendations[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 575-581. DOI: 10.3969/j.issn.1674-9081.2019.06.005
[8]	Zi-jia LIU, Hui-zhen HUANG, Yu-guang HUANG. From Enhanced Recovery after Surgery to Day-case Surgery: Interpretation on Guidelines for Day-case Surgery 2019: Guidelines from the Association of Anaesthetists and the British Association of Day Surgery[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 570-574. DOI: 10.3969/j.issn.1674-9081.2019.06.004
[9]	Xiao-dong TIAN, Yin-mo YANG. Concept Renewal Leads to Behavior Progress: Interpretation on the Surgical Part of Consensus on ERAS and Guidelines for Pathway Management in China (2018)[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(6): 485-489. DOI: 10.3969/j.issn.1674-9081.2018.06.002
[10]	Tian-long WANG, Yu-guang HUANG. Campaigning for the Transformation from Anesthesiology to Perioperative Medicine: Interpretation on the Anesthesia Part of Consensus on ERAS and Guidelines for the Pathway Management in China (2018)[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(6): 481-484. DOI: 10.3969/j.issn.1674-9081.2018.06.001

Cited By

Cited by

Periodical cited type(9)

1.	王清清，张利，刘伟，侯爱画，赵啸虎，刘泽. 侯爱画教授应用扶正护膜方化裁治疗神经内分泌肿瘤经验. 云南中医中药杂志. 2024(01): 8-13 .
2.	吕高星，赵建华. CT与MRI诊断胆囊副神经节瘤案例分析. CT理论与应用研究. 2024(05): 647-653 .
3.	张臻，汤艳，王梦杰，郑拓拓，樊志敏. 直肠神经内分泌肿瘤研究进展. 中外医学研究. 2024(26): 177-180 .
4.	李帅. ~(18)F-MFBG的制备及临床应用进展. 国际放射医学核医学杂志. 2024(11): 709-713 .
5.	刘丰，石嫣，芦丽芳，韩飞，姚景春. 喉神经内分泌癌22例生存情况分析. 肿瘤研究与临床. 2023(08): 622-625 .
6.	徐胜楠，楚海涛，李春朋，刘文丽，卫晓静. PHPF管理模式在肿瘤术后患者难愈性伤口护理中的应用. 齐鲁护理杂志. 2023(20): 9-12 .
7.	罗海静，赵颖海. 神经内分泌肿瘤相关生物指标应用的研究进展. 现代医药卫生. 2023(23): 4073-4077+4083 .
8.	杨逸凡，黎传奎，李其才，王祖义. 基于SEER数据库的肺大细胞神经内分泌癌预后影响因素分析. 淮海医药. 2023(06): 551-555+559 .
9.	方洒，施育鹏，时永全，韩霜. 十二指肠非壶腹区神经内分泌肿瘤的临床特征分析. 胃肠病学. 2023(07): 437-440 .

Other cited types(5)

Get Citation

PDF

XML

Article Metrics

Article views (1595) PDF downloads (503) Cited by(14)

Address：	Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
Tel：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
Copyright of website：	Editorial Office of Medical Journal of Peking Union Medical College Hospital

Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)

Abstract

References

Related Articles

Cited by

Periodical cited type(9)

Other cited types(5)

Catalog

Article Metrics

Related

Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)

Abstract

References

Related Articles

Cited by

Periodical cited type(9)

Other cited types(5)

Catalog

Article Metrics

Related

Export File

Citation

Format

Content